| Dr Thomas Parker Buck, MD | |
|
71 Haynes St, Manchester, CT 06040-4131 | |
| (860) 647-6487 | |
| (860) 647-6447 |
| Full Name | Dr Thomas Parker Buck |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 17 Years |
| Location | 71 Haynes St, Manchester, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356591788 | NPI | - | NPPES |
| 008040445 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 050836 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holyoke Medical Center | Holyoke, MA | Hospital |
| Harrington Memorial Hospital-1 | Southbridge, MA | Hospital |
| Manchester Memorial Hospital | Manchester, CT | Hospital |
| Waterbury Hospital | Waterbury, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eastern Connecticut Pathology Consultants, Pc | 3173511581 | 16 |
| Eastern Connecticut Pathology Consultants, Pc | 3173511581 | 16 |
News Archive
Continuously measuring blood pressure may help predict heart disease and related deaths among individuals with treatment-resistant hypertension, while blood pressure readings taken in a medical office do not appear to predict future heart risks, according to a report in November 24 issue of Archives of Internal Medicine.
Orlando Internal Medicine, an eight-provider practice, is expediting the collection of patient co-payments, deductibles and payer reimbursement through its use of self-service solutions from Greatwater Software and NCR Corporation/
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
Researchers in the UK have developed a prognostic tool that accurately predicts whether patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent causes coronavirus disease 2019 (COVID-19) – will require admission to the intensive care unit (ICU), die, or survive without escalation to ICU.
› Verified 4 days ago
| Entity Name | Eastern Connecticut Pathology Consultants, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558326991 PECOS PAC ID: 3173511581 Enrollment ID: O20040504001328 |
News Archive
Continuously measuring blood pressure may help predict heart disease and related deaths among individuals with treatment-resistant hypertension, while blood pressure readings taken in a medical office do not appear to predict future heart risks, according to a report in November 24 issue of Archives of Internal Medicine.
Orlando Internal Medicine, an eight-provider practice, is expediting the collection of patient co-payments, deductibles and payer reimbursement through its use of self-service solutions from Greatwater Software and NCR Corporation/
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
Researchers in the UK have developed a prognostic tool that accurately predicts whether patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent causes coronavirus disease 2019 (COVID-19) – will require admission to the intensive care unit (ICU), die, or survive without escalation to ICU.
› Verified 4 days ago
| Entity Name | Connecticut Gi Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023124625 PECOS PAC ID: 9830110758 Enrollment ID: O20070112000011 |
News Archive
Continuously measuring blood pressure may help predict heart disease and related deaths among individuals with treatment-resistant hypertension, while blood pressure readings taken in a medical office do not appear to predict future heart risks, according to a report in November 24 issue of Archives of Internal Medicine.
Orlando Internal Medicine, an eight-provider practice, is expediting the collection of patient co-payments, deductibles and payer reimbursement through its use of self-service solutions from Greatwater Software and NCR Corporation/
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
Researchers in the UK have developed a prognostic tool that accurately predicts whether patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent causes coronavirus disease 2019 (COVID-19) – will require admission to the intensive care unit (ICU), die, or survive without escalation to ICU.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Parker Buck, MD Po Box 902, New Haven, CT 06504-0902 Ph: (203) 397-8000 | Dr Thomas Parker Buck, MD 71 Haynes St, Manchester, CT 06040-4131 Ph: (860) 647-6487 |
News Archive
Continuously measuring blood pressure may help predict heart disease and related deaths among individuals with treatment-resistant hypertension, while blood pressure readings taken in a medical office do not appear to predict future heart risks, according to a report in November 24 issue of Archives of Internal Medicine.
Orlando Internal Medicine, an eight-provider practice, is expediting the collection of patient co-payments, deductibles and payer reimbursement through its use of self-service solutions from Greatwater Software and NCR Corporation/
Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.
Researchers in the UK have developed a prognostic tool that accurately predicts whether patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent causes coronavirus disease 2019 (COVID-19) – will require admission to the intensive care unit (ICU), die, or survive without escalation to ICU.
› Verified 4 days ago
Dr. Dennis G O'neill, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-647-6487 Fax: 860-647-6447 | |
Michael Aaron Hitchcock, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-647-6487 | |
Dr. Devbala Patel, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-647-6487 Fax: 860-647-6447 | |
Dr. Kevin Timothy Pelland Jr., M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes Street, Pathology Dept, Manchester, CT 06040 Phone: 606-647-6487 | |
Dr. Michele B. Conlon, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-647-6487 Fax: 860-647-6447 | |
Dr. Robert A Schwartz, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 71 Haynes St, Manchester, CT 06040 Phone: 860-647-6487 Fax: 860-647-6447 |